RxDoctor Payments Data

Praveen Moolamalla, MD

Psychiatry · McKinney, TXNPI 1114935954

Payments from drug & device makers

$5,915in general payments, 2019–2025

Across 341 payments — averaging $17.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Otsuka America Pharmaceutical, Inc.$863
  • Takeda Pharmaceuticals U.S.A., Inc.$719
  • Sunovion Pharmaceuticals Inc.$668
  • Lundbeck LLC$439
  • Vanda Pharmaceuticals Inc.$277
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$5,915100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,915 in reported general payments places this provider in the 85th percentile of 2,238 psychiatry providers in Texas.

See all psychiatry providers in Texas

Medicare billing

Part B allowed, 2024
$133,602
Medicare patients
134
Services billed
1,568

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl55$82,444
RexultiBrexpiprazole12$22,390
Lurasidone Hcl20$15,111
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl79$12,701
FetzimaLevomilnacipran Hcl20$12,338
TrintellixVortioxetine Hydrobromide23$10,899
BelsomraSuvorexant21$8,696
VyvanseLisdexamfetamine Dimesylate22$8,590
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine238$8,560
Aripiprazole51$6,854
Ziprasidone Hcl54$6,260
Chlorpromazine Hcl18$5,653
Vilazodone Hcl71$4,171
Eszopiclone63$3,721
Desvenlafaxine Succinate ErDesvenlafaxine Succinate35$3,184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar, Fetzima$1,494$94,78275 claims
Otsuka America Pharmaceutical, Inc.Rexulti$863$22,39012 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$719$19,48945 claims
MerckBelsomra$188$8,69621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,238 psychiatry providers in Texas.

Other psychiatry in McKinney

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →